NCT04544826View on ClinicalTrials.gov

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

August 5, 2021

Study Completion Date

August 5, 2021

Conditions
Healthy
Interventions
DRUG

JNJ-77474462

JNJ-77474462 will be administered as SC injection.

DRUG

Placebo

Matching placebo to JNJ-77474462 will be administered as SC injection.

Trial Locations (1)

4006

Nucleus Network, Q-Pharm Pty Ltd, Herston

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04544826 - A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses | Biotech Hunter | Biotech Hunter